

Journal Information

Journal Title	CANCER TREATMENT REVIEWS
Publisher	ELSEVIER SCI LTD
ISSN	0305-7372
E-ISSN	1532-1967
Database	Clarivate
Domain	Health Sciences, Life Sciences, Physical Sciences, Social Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019	✓	✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Artificial intelligence-enabled drug discovery: A growing but largely early-stage clinical pipeline 2026-12 Vol. 151 Pages 103223 Authors: Waqas Haque, Kareena Sai-Palm, Iemaan Rana et al. DOI: 10.1016/j.ctrv.2026.103223
T-cell engagers in small-cell lung cancer: current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation Workshop 2026-12 Vol. 151 Pages 103201 Authors: May-Lucie Meyer, Solange Peters, Myung-Ju Ahn et al. DOI: 10.1016/j.ctrv.2026.103201
The prognostic value of pathological response in soft tissue sarcoma: A systematic review 2026-12 Vol. 151 Pages 103219 Authors: Bauke H.G. van Riet, Stijn J.C. van der Burg, Tom van der Klaauw et al. DOI: 10.1016/j.ctrv.2026.103219
Systemic therapy for metastatic nasopharyngeal carcinoma in the immunotherapy era: A critical review 2026-12 Vol. 151 Pages 103214 Authors: Weijie Wen, Jishi Li, Yuan Qu et al. DOI: 10.1016/j.ctrv.2026.103214
CDH1 germline carriers and diffuse gastric Cancer: Are we ready for personalized surveillance and prevention? 2026-12 Vol. 151 Pages 103225 Authors: Mara Cruellas, Joaquín Castillo-Iturra, Tian V. Tian et al. DOI: 10.1016/j.ctrv.2026.103225

Incidence and severity of nausea and vomiting with trastuzumab deruxtecan: a systematic review and meta-analysis

2026-12 Vol. 151 Pages 103239

Authors: J. Leigh, C.F. Theriau, B. Alshamsan et al.

DOI: 10.1016/j.ctrv.2026.103239

Immune checkpoint inhibitors in platinum-resistant ovarian cancer: Clinical disappointments, biological lessons, and the reopening of therapeutic opportunities

2026-12 Vol. 151 Pages 103237

Authors: Elena Giudice, Andrea Spinazzola, Charalampos S. Floudas et al.

DOI: 10.1016/j.ctrv.2026.103237

Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma

2026-12 Vol. 151 Pages 103233

Authors: María José Juan Fita, Urbano Anido, Luis Bataller et al.

DOI: 10.1016/j.ctrv.2026.103233

Exercise as anticancer medicine? Evidence, mechanisms and implementation in oncology

2026-12 Vol. 151 Pages 103222

Authors: Manuela Schmidinger, Irene Huebner-Resch, Shahrokh F. Shariat

DOI: 10.1016/j.ctrv.2026.103222

Role of maintaining the TKI backbone in oncogene-driven NSCLC after progression

2026-12 Vol. 151 Pages 103235

Authors: Francesca Piazza, Rishi Sharma, Alessandra Esposito et al.

DOI: 10.1016/j.ctrv.2026.103235